Grace Therapeutics (GRCE)

• Market cap: $33.8M
• 1 day: 0.48%
• 5 days: -9.57%
• 1 month: -8.37%
• 3 months: -7.14%
• 6 months: -44.53%
• Year to date: -43.17%
• 1 year: -28.03%
• 5 years: -91.07%
• 10 years: -97.2%
• Sector: Healthcare
• Industry: Biotechnology

About: Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.

Employees: 5